You are here

Chemosensitivity Tumor Assay & Interphase Cytogenetics

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 22051
Amount: $48,260.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1993
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
2601 Bellefontaine, Suite C201
Houston, TX 77025
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Howard G. Gratzner
 (713) 661-7617
Business Contact
Phone: () -
Research Institution
N/A
Abstract

The objective is to develop a new method for in vitro chemosensitivity and chemoresistance testing of cancer. Phase I will be concerned with an in vitro cell culture system to develop the method. The method will be based upon the use of short-term culture of extirpated tumor cells; this system will monitor the effects of chemotherapeutic drugs on cell proliferation by means of the immunofluorescent detection of bromodeoxyuridine as a measure of DNA synthesis. In order to discriminate tumor cells from the normal diploid stromal cells in the culture, the karyotype of the interphase tumor cells will be will be predetermined by in situ fluorescence hybridation (FISH) prior to BrdUrd pulsing of the cultures, and FISH then performed on the BrdUrd-labeled cells. The dual fluorescence image analysis of IdUrd incorporation and selected FISH probes will distinguish the tumor cells from non-tumor cells in the culture. Corroboration of the identity of tumor cells will be made by a cytopathologist. The method combines the assessment of drug sensitivity of the tumor with the prognostic power of karyotyping.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government